Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PTCT

PTCT - PTC Therapeutics Inc Stock Price, Fair Value and News

$75.61+0.12 (+0.16%)
Market Closed

90/100

PTCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

90/100

PTCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$112.88

Target 3M

$90.6

Target 6M

$101.59

PTCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTCT Price Action

Last 7 days

0.1%

Last 30 days

-2.6%

Last 90 days

11.0%

Trailing 12 Months

67.3%

PTCT RSI Chart

PTCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTCT Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

8.08

Price/Sales (Trailing)

3.41

EV/EBITDA

6.93

Price/Free Cashflow

8.61

PTCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$112.88

Target 3M

$90.6

Target 6M

$101.59

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

1.8B

Rev. Growth (Yr)

7.23%

Rev. Growth (Qtr)

17.96%

PTCT Earnings

Earnings (TTM)

751.7M

Earnings Growth (Yr)

114.9%

Earnings Growth (Qtr)

124.51%

PTCT Profitability

EBT Margin

41.65%

Return on Equity

-482.62%

Return on Assets

28.43%

Free Cashflow Yield

11.62%

PTCT Investor Care

Shares Dilution (1Y)

4.10%

Diluted EPS (TTM)

8.56

PTCT Alerts

  • 7 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.8B1.8B1.8B0
2024927.6M900.5M900.7M806.8M
2023770.4M818.7M798.2M937.8M
2022569.4M618.2M696.6M698.8M
2021430.4M471.9M492.2M538.6M
2020321.7M311.4M358.4M380.8M
2019261.8M278.5M296.4M307.0M
2018203.7M224.5M236.3M264.2M
201790.3M122.5M141.3M174.1M
201648.2M57.0M70.2M82.7M
201523.5M28.6M36.7M36.8M
201436.8M31.6M17.0M25.2M
201328.6M27.8M36.9M34.7M
2012113.1M115.9M36.7M33.9M
2011000105.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About PTC Therapeutics Inc

PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
 CEO
 WEBSITEptcbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1402

PTC Therapeutics Inc Frequently Asked Questions

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of PTC Therapeutics Inc is 6.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PTCT's fair value in chart for subscribers.

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

As of Wed Jan 28 2026, PTCT's PE ratio (Price to Earnings) is 8.08 and Price to Sales (PS) ratio is 3.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, PTC Therapeutics Inc has provided 0.122 (multiply by 100 for percentage) rate of return.